SOURCE: INSYS Therapeutics

Insys Therapeutics

November 20, 2013 08:00 ET

Insys Therapeutics to Present at Upcoming Conferences

PHOENIX, AZ--(Marketwired - Nov 20, 2013) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the following upcoming investor conferences:

  • The 25th Annual Piper Jaffray Healthcare Conference taking place at The New York Palace on December 3-4, 2013 in New York City. Management is scheduled to present on Tuesday, December 3, 2013 at 2:30 p.m. EST.
  • The 24th Annual Oppenheimer Healthcare Conference taking place at the Crowne Plaza Hotel on December 10-11, 2013 in New York City. Management is scheduled to present on Tuesday, December 10, 2013 at 3:55 p.m. EST.

During these presentations, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of these presentations during the event, please visit: A replay of each webcast will be available for 30 days after the initial presentation.

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.

Contact Information

  • Contacts:
    Darryl S. Baker
    Chief Financial Officer
    Insys Therapeutics, Inc.

    Lisa M. Wilson
    In-Site Communications, Inc.